Compare AMZE & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMZE | PFSA |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.1M | 9.1M |
| IPO Year | 2021 | N/A |
| Metric | AMZE | PFSA |
|---|---|---|
| Price | $0.40 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.2M | ★ 54.2M |
| Earning Date | 11-14-2025 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,245,143.00 | N/A |
| Revenue This Year | $6,741.66 | N/A |
| Revenue Next Year | $100.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 369.95 | 122.22 |
| 52 Week Low | $0.24 | $0.07 |
| 52 Week High | $19.44 | $12.76 |
| Indicator | AMZE | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | N/A |
| Support Level | $0.37 | N/A |
| Resistance Level | $0.43 | N/A |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 81.51 | 0.00 |
Amaze Holdings Inc is engaged in producer of low carb, low calorie, premium wines in the United States. The company offers bold, crisp, and creamy wines that embody health, warmth, and a deeper connection to wellness and an active lifestyle. The company currently sell seven proprietary varietals: Cabernet Sauvignon, Pinot Noir, Chardonnay, Sauvignon Blanc, Rose, Sparkling Rose, and a limited Reserve Napa Cabernet Sauvignon.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.